TransMedics Group (TMDX) Misses Q2 EPS by 11c

TransMedics Group (NASDAQ: TMDX) reported Q2 EPS of ($0.39), $0.11 worse than the analyst estimate of ($0.28). Revenue for the quarter came in at $8.2 million versus the consensus estimate of $7.8 million.

Cash, cash equivalents and marketable securities were $112.2 million as of June 30, 2021.

For earnings history and earnings-related data on TransMedics Group (TMDX) click here.

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Jefferies upgrades Five Below to Buy, sees path to TJX-like re-rating
• Azitra, Inc. (AZTR) Tops Q2 EPS by 54c